Short Interest in Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Expands By 172.3%

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,567,900 shares, a growth of 172.3% from the June 15th total of 1,310,364 shares. Approximately 5.8% of the company’s stock are short sold. Based on an average daily volume of 1,355,663 shares, the short-interest ratio is currently 2.6 days.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ:DMRA opened at $28.00 on Tuesday. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33. The firm has a 50-day moving average price of $24.38 and a two-hundred day moving average price of $25.49. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -5.02 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $40,000. Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $266,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $49,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $334,000. Finally, Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $76,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Analyst Upgrades and Downgrades

DMRA has been the subject of several analyst reports. Royal Bank Of Canada began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target for the company. HC Wainwright began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They issued a “buy” rating and a $45.00 price target for the company. Finally, TD Cowen began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $42.43.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.